Review



nmol l tumor necrosis factor  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 97

    Structured Review

    R&D Systems nmol l tumor necrosis factor
    Nmol L Tumor Necrosis Factor, supplied by R&D Systems, used in various techniques. Bioz Stars score: 97/100, based on 1779 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+protein/Recombinant+Human+TNF-alpha+Protein/pmc13054578-103-43-49
    Average 97 stars, based on 1779 article reviews
    nmol l tumor necrosis factor - by Bioz Stars, 2026-11
    97/100 stars

    Images

    Related Articles

    SDS Page:

    Article Title: SFX-01 is therapeutic against myeloproliferative disorders caused by activating mutations in Shp2.
    Article Snippet: .. Protein-containing samples in SDS-PAGE sample buffer were subjected to electrophoresis and immunoblotting using the following primary antibodies: SFN (1:1000, in-house), Shp2 (1:1000, Abcam #32083) for recombinant protein or (R&D Systems #AF1894) for immunoprecipitation experiments, GAPDH (1:5000, CST #2118) and an anti-rabbit secondary antibody (1:2500, CST #7074). ..

    Article Title: SFX-01 is therapeutic against myeloproliferative disorders caused by activating mutations in Shp2
    Article Snippet: .. Protein-containing samples in SDS-PAGE sample buffer were subjected to electrophoresis and immunoblotting using the following primary antibodies: SFN (1:1000, in-house), Shp2 (1:1000, Abcam #32083) for recombinant protein or (R&D Systems #AF1894) for immunoprecipitation experiments, GAPDH (1:5000, CST #2118) and an anti-rabbit secondary antibody (1:2500, CST #7074). ..

    Electrophoresis:

    Article Title: SFX-01 is therapeutic against myeloproliferative disorders caused by activating mutations in Shp2.
    Article Snippet: .. Protein-containing samples in SDS-PAGE sample buffer were subjected to electrophoresis and immunoblotting using the following primary antibodies: SFN (1:1000, in-house), Shp2 (1:1000, Abcam #32083) for recombinant protein or (R&D Systems #AF1894) for immunoprecipitation experiments, GAPDH (1:5000, CST #2118) and an anti-rabbit secondary antibody (1:2500, CST #7074). ..

    Article Title: SFX-01 is therapeutic against myeloproliferative disorders caused by activating mutations in Shp2
    Article Snippet: .. Protein-containing samples in SDS-PAGE sample buffer were subjected to electrophoresis and immunoblotting using the following primary antibodies: SFN (1:1000, in-house), Shp2 (1:1000, Abcam #32083) for recombinant protein or (R&D Systems #AF1894) for immunoprecipitation experiments, GAPDH (1:5000, CST #2118) and an anti-rabbit secondary antibody (1:2500, CST #7074). ..

    Western Blot:

    Article Title: SFX-01 is therapeutic against myeloproliferative disorders caused by activating mutations in Shp2.
    Article Snippet: .. Protein-containing samples in SDS-PAGE sample buffer were subjected to electrophoresis and immunoblotting using the following primary antibodies: SFN (1:1000, in-house), Shp2 (1:1000, Abcam #32083) for recombinant protein or (R&D Systems #AF1894) for immunoprecipitation experiments, GAPDH (1:5000, CST #2118) and an anti-rabbit secondary antibody (1:2500, CST #7074). ..

    Article Title: SFX-01 is therapeutic against myeloproliferative disorders caused by activating mutations in Shp2
    Article Snippet: .. Protein-containing samples in SDS-PAGE sample buffer were subjected to electrophoresis and immunoblotting using the following primary antibodies: SFN (1:1000, in-house), Shp2 (1:1000, Abcam #32083) for recombinant protein or (R&D Systems #AF1894) for immunoprecipitation experiments, GAPDH (1:5000, CST #2118) and an anti-rabbit secondary antibody (1:2500, CST #7074). ..

    Recombinant:

    Article Title: SFX-01 is therapeutic against myeloproliferative disorders caused by activating mutations in Shp2.
    Article Snippet: .. Protein-containing samples in SDS-PAGE sample buffer were subjected to electrophoresis and immunoblotting using the following primary antibodies: SFN (1:1000, in-house), Shp2 (1:1000, Abcam #32083) for recombinant protein or (R&D Systems #AF1894) for immunoprecipitation experiments, GAPDH (1:5000, CST #2118) and an anti-rabbit secondary antibody (1:2500, CST #7074). ..

    Article Title: SFX-01 is therapeutic against myeloproliferative disorders caused by activating mutations in Shp2
    Article Snippet: .. Protein-containing samples in SDS-PAGE sample buffer were subjected to electrophoresis and immunoblotting using the following primary antibodies: SFN (1:1000, in-house), Shp2 (1:1000, Abcam #32083) for recombinant protein or (R&D Systems #AF1894) for immunoprecipitation experiments, GAPDH (1:5000, CST #2118) and an anti-rabbit secondary antibody (1:2500, CST #7074). ..

    Article Title: The co-delivery of Programmed Death 1 ligands enhances and prolongs rAAV-mediated gene expression in pre-immunized mice
    Article Snippet: NP-40 lysates of transfected 293T cells were precleared with HisPur Ni-NTA Magnetic Beads (Thermo Scientific). .. Lysates were collected, supplied with 2.5 μg of PD1-His (cat# 8986-PD-100, R&D Systems) recombinant protein, and incubated at 4 °C overnight. ..

    Article Title: Substituted 1,2,4-triazoles as TYK2 inhibitors
    Article Snippet: .. A 10-point dilution series of test compound (top dose 10 uM, 1:5 dilution) was added to the well using the liquid dispenser (Tecan D300e) and incubated for 1 hour at 37 C. Then human IL-12 recombinant protein (R&D Systems) was added to the well at the final concentration of 10 ng/ml and incubated for 15 minutes at 37 C. Cell lysates were prepared and analyzed by Phospho STAT4 (Tyr693) Kit (Meso Scale Discovery) following manufacturer's protocol. ..

    Article Title: Identification of a SNAI1 enhancer RNA that drives cancer cell plasticity.
    Article Snippet: Anti-BRD4 antibody (Cell Signaling Technology; 13440), anti-YTHDC1 antibody (Cell Signaling Technology; 77422s), or normal rabbit IgG was incubated with MDA-MB-231 cell lysates for 16 h at 4 °C. .. For in vitro RIP, 10 pmol of in vitro-transcribed SNAI1e was incubated with 2 μg recombinant FLAG-SMURF2 protein (Sigma‒Aldrich; SRP0228) or FLAG-BRD4 BD1/2 recombinant protein (R&D systems; SP-600) for 16 h at 4 °C as described previously21. .. Gonçalves, LUMC, Leiden, The Netherlands), using Lipofectamine 3000 (Thermo Fisher Scientific; L3000015).

    Immunoprecipitation:

    Article Title: SFX-01 is therapeutic against myeloproliferative disorders caused by activating mutations in Shp2.
    Article Snippet: .. Protein-containing samples in SDS-PAGE sample buffer were subjected to electrophoresis and immunoblotting using the following primary antibodies: SFN (1:1000, in-house), Shp2 (1:1000, Abcam #32083) for recombinant protein or (R&D Systems #AF1894) for immunoprecipitation experiments, GAPDH (1:5000, CST #2118) and an anti-rabbit secondary antibody (1:2500, CST #7074). ..

    Article Title: SFX-01 is therapeutic against myeloproliferative disorders caused by activating mutations in Shp2
    Article Snippet: .. Protein-containing samples in SDS-PAGE sample buffer were subjected to electrophoresis and immunoblotting using the following primary antibodies: SFN (1:1000, in-house), Shp2 (1:1000, Abcam #32083) for recombinant protein or (R&D Systems #AF1894) for immunoprecipitation experiments, GAPDH (1:5000, CST #2118) and an anti-rabbit secondary antibody (1:2500, CST #7074). ..

    other:

    Article Title: Bispecific antibody
    Article Snippet: The clones CD19-1(Bi) to CD19-5(Bi) or control antibody were added thereto, and IgM contained in the culture supernatant after activation treatment was quantified by ELISA (ThermoFisher, Serial No. BMS 2098).

    Article Title: Identification of a SNAI1 enhancer RNA that drives cancer cell plasticity.
    Article Snippet: MDA-MB-231 cells stably expressing Cas9 (Addgene; 98290) were transduced with gRNA expression constructs by lentivirus infection.

    Article Title: Bispecific antibody
    Article Snippet: Note here that for immobilization of the recombinant proteins, Series S Sensor Chip CM5 Sensor Chip (GE Health Care, serial number 29-1049-88) was used.

    Incubation:

    Article Title: The co-delivery of Programmed Death 1 ligands enhances and prolongs rAAV-mediated gene expression in pre-immunized mice
    Article Snippet: NP-40 lysates of transfected 293T cells were precleared with HisPur Ni-NTA Magnetic Beads (Thermo Scientific). .. Lysates were collected, supplied with 2.5 μg of PD1-His (cat# 8986-PD-100, R&D Systems) recombinant protein, and incubated at 4 °C overnight. ..

    Article Title: Substituted 1,2,4-triazoles as TYK2 inhibitors
    Article Snippet: .. A 10-point dilution series of test compound (top dose 10 uM, 1:5 dilution) was added to the well using the liquid dispenser (Tecan D300e) and incubated for 1 hour at 37 C. Then human IL-12 recombinant protein (R&D Systems) was added to the well at the final concentration of 10 ng/ml and incubated for 15 minutes at 37 C. Cell lysates were prepared and analyzed by Phospho STAT4 (Tyr693) Kit (Meso Scale Discovery) following manufacturer's protocol. ..

    Article Title: Identification of a SNAI1 enhancer RNA that drives cancer cell plasticity.
    Article Snippet: Anti-BRD4 antibody (Cell Signaling Technology; 13440), anti-YTHDC1 antibody (Cell Signaling Technology; 77422s), or normal rabbit IgG was incubated with MDA-MB-231 cell lysates for 16 h at 4 °C. .. For in vitro RIP, 10 pmol of in vitro-transcribed SNAI1e was incubated with 2 μg recombinant FLAG-SMURF2 protein (Sigma‒Aldrich; SRP0228) or FLAG-BRD4 BD1/2 recombinant protein (R&D systems; SP-600) for 16 h at 4 °C as described previously21. .. Gonçalves, LUMC, Leiden, The Netherlands), using Lipofectamine 3000 (Thermo Fisher Scientific; L3000015).

    Concentration Assay:

    Article Title: Substituted 1,2,4-triazoles as TYK2 inhibitors
    Article Snippet: .. A 10-point dilution series of test compound (top dose 10 uM, 1:5 dilution) was added to the well using the liquid dispenser (Tecan D300e) and incubated for 1 hour at 37 C. Then human IL-12 recombinant protein (R&D Systems) was added to the well at the final concentration of 10 ng/ml and incubated for 15 minutes at 37 C. Cell lysates were prepared and analyzed by Phospho STAT4 (Tyr693) Kit (Meso Scale Discovery) following manufacturer's protocol. ..

    In Vitro:

    Article Title: Identification of a SNAI1 enhancer RNA that drives cancer cell plasticity.
    Article Snippet: Anti-BRD4 antibody (Cell Signaling Technology; 13440), anti-YTHDC1 antibody (Cell Signaling Technology; 77422s), or normal rabbit IgG was incubated with MDA-MB-231 cell lysates for 16 h at 4 °C. .. For in vitro RIP, 10 pmol of in vitro-transcribed SNAI1e was incubated with 2 μg recombinant FLAG-SMURF2 protein (Sigma‒Aldrich; SRP0228) or FLAG-BRD4 BD1/2 recombinant protein (R&D systems; SP-600) for 16 h at 4 °C as described previously21. .. Gonçalves, LUMC, Leiden, The Netherlands), using Lipofectamine 3000 (Thermo Fisher Scientific; L3000015).



    Similar Products

    97
    R&D Systems nmol l tumor necrosis factor
    Nmol L Tumor Necrosis Factor, supplied by R&D Systems, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+protein/Recombinant+Human+TNF-alpha+Protein/pmc13054578-103-43-49
    Average 97 stars, based on 1 article reviews
    nmol l tumor necrosis factor - by Bioz Stars, 2026-11
    97/100 stars
      Buy from Supplier

    94
    Thermo Fisher recombinant human interleukin il 4
    Effects of prednisolone on macrophage polarization and regulatory T (Treg) cell induction mediated by cADSCs. (a) Representative flow cytometry plots showing cluster designation (CD) 80 and CD206 expression in CD14 + DH82 cells. Cells cultured alone under control conditions or stimulated with interleukin <t>(IL)-4/IL-13</t> or lipopolysaccharide (LPS)/interferon (IFN)-γ are shown, together with DH82 cells co-cultured with cADSCs pretreated with prednisolone at the indicated concentrations (0–100 μM) under LPS/IFN-γ stimulation. (b) Quantitative analysis of macrophage subsets, defined as CD14 + CD80 + CD206 - , CD14 + CD80 − CD206 + , CD14 + CD80 + CD206 + , and CD14 + CD80 − CD206 - cells. IL-4/IL-13 stimulation was included as an M2-polarizing control, whereas LPS/IFN-γ stimulation induced M1-like polarization. (c) Representative flow cytometry plots showing CD25 and Foxp3 expression in CD4 + T cells after co-culture of PBMCs with cADSCs pretreated with prednisolone. Red boxes indicate CD25 + Foxp3 + Treg cells. (d) Quantification of CD25 + Foxp3 + Treg cells within the CD4 + T-cell population. Data are presented as mean ± SD from three independent experiments using cADSCs derived from three independent donors. * p < 0.05 vs. control or PBMCs alone; † p < 0.05 vs. LPS/IFN-γ.
    Recombinant Human Interleukin Il 4, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+protein/Human+Interleukin+4+(IL-4)+Recombinant+Protein/pmc13653428-104-28-32
    Average 94 stars, based on 1 article reviews
    recombinant human interleukin il 4 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    93
    R&D Systems recombinant human rankl
    Effects of prednisolone on macrophage polarization and regulatory T (Treg) cell induction mediated by cADSCs. (a) Representative flow cytometry plots showing cluster designation (CD) 80 and CD206 expression in CD14 + DH82 cells. Cells cultured alone under control conditions or stimulated with interleukin <t>(IL)-4/IL-13</t> or lipopolysaccharide (LPS)/interferon (IFN)-γ are shown, together with DH82 cells co-cultured with cADSCs pretreated with prednisolone at the indicated concentrations (0–100 μM) under LPS/IFN-γ stimulation. (b) Quantitative analysis of macrophage subsets, defined as CD14 + CD80 + CD206 - , CD14 + CD80 − CD206 + , CD14 + CD80 + CD206 + , and CD14 + CD80 − CD206 - cells. IL-4/IL-13 stimulation was included as an M2-polarizing control, whereas LPS/IFN-γ stimulation induced M1-like polarization. (c) Representative flow cytometry plots showing CD25 and Foxp3 expression in CD4 + T cells after co-culture of PBMCs with cADSCs pretreated with prednisolone. Red boxes indicate CD25 + Foxp3 + Treg cells. (d) Quantification of CD25 + Foxp3 + Treg cells within the CD4 + T-cell population. Data are presented as mean ± SD from three independent experiments using cADSCs derived from three independent donors. * p < 0.05 vs. control or PBMCs alone; † p < 0.05 vs. LPS/IFN-γ.
    Recombinant Human Rankl, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+protein/Recombinant+Human+TRANCE%2FRANK+L%2FTNFSF11+Protein/pmc13768825-29-58-62
    Average 93 stars, based on 1 article reviews
    recombinant human rankl - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    97
    R&D Systems bone morphogenetic protein 4 bmp4
    Exploring single gastruloid heterogeneity. (a) Shown are sequential bright-field (upper row) and fluorescence (lower row) images using widefield microscopy of a single microraft possessing hPSCs expressing a SOX2-mCitrine reporter. <t>BMP4</t> was added to the cultures at time 0 h to initiate gastruloid formation. Scale bars, 100 μ m. (b) Schematic of the live time-series imaging and end point RNA-seq workflow. SOX2 dynamics and gene expression profiles of single gastruloids were acquired. 16D latent representations were formed from individual YX slices of imaging time-series (widefield microscopy) of each gastruloid and visualized via UMAP dimensionality reduction. Gastruloid heterogeneity across and within experimental batches was assessed using the image-based latent representations and sequence-based gene expression profiles.
    Bone Morphogenetic Protein 4 Bmp4, supplied by R&D Systems, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+protein/Recombinant+Human+BMP-4+Protein/pmc13759244-228-30-36
    Average 97 stars, based on 1 article reviews
    bone morphogenetic protein 4 bmp4 - by Bioz Stars, 2026-11
    97/100 stars
      Buy from Supplier

    92
    BPS Bioscience recombinant egfr protein
    High-throughput screening identifies abemaciclib as a selective suppressor of osimertinib-resistant mutant <t>EGFR</t> signaling. A Schematic overview of the drug-screening protocol for the EGFR-LTC inhibitor abemaciclib. B A high-throughput screening assay of ~125,000 compounds was performed to measure cell proliferation of Ba/F3 cells expressing different mutant types of EGFR with or without IL-3. 1st: First-round drug selection; 2nd: second-round drug selection; 3rd: third-round drug selection. LT: <t>L858R/T790M;</t> LTC: <t>L858R/T790M/C797S.</t> #: The drug was ineffective; *: the drug did not dissolve; NA: not applicable. C A high-throughput screening assay of ~125,000 compounds was performed to measure cell proliferation in EGFR-TKI resistant Ba/F3 cells expressing mutant EGFR variants. D Cells were treated with abemaciclib at the indicated concentration for 72 hours. Cell viability was analyzed using the MTS assay, and the IC50 values were comparable (on the right). The error bars represent the means ± SDs; n =3. Ba/F3 EGFR-LTC ( E ) or Ba/F3 EGFR DTC cells ( F ) were treated with abemaciclib in the absence or presence of IL-3 at the indicated concentration for 72 hours, and cell viability was analyzed using the MTS assay. G EGFR-LTC cells were treated with brigatinib in the absence or presence of IL-3 at the indicated concentration for 72 hours, and cell viability was analyzed using the MTS assay. EGFR-LT cells were treated with paclitaxel ( H ), cisplatin ( I ), and osimertinib ( J ) in the absence or presence of IL-3 at the indicated concentration for 72 hours, and cell viability was analyzed using the MTS assay. K The proportions of H1975-LTC cells in the sub-G1 phase were determined after abemaciclib or osimertinib treatment. L Apoptosis assays were performed in H1975-LTC cells treated with the pancaspase inhibitor Z-VAD-FMK at the indicated concentration for 72 hours. M H1975-LTC cells were treated with the indicated concentration of abemaciclib for 48 hours, after which the cell lysates were harvested. Protein extracts were immunoblotted with the indicated antibodies. β-Actin served as a loading control in all the Western blotting panels
    Recombinant Egfr Protein, supplied by BPS Bioscience, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+protein/EGFR%2C+His-tag%2C+GST-tag+Recombinant/pmc13756994-93-4-15
    Average 92 stars, based on 1 article reviews
    recombinant egfr protein - by Bioz Stars, 2026-11
    92/100 stars
      Buy from Supplier

    93
    R&D Systems human angiotensin converting enzyme
    High-throughput screening identifies abemaciclib as a selective suppressor of osimertinib-resistant mutant <t>EGFR</t> signaling. A Schematic overview of the drug-screening protocol for the EGFR-LTC inhibitor abemaciclib. B A high-throughput screening assay of ~125,000 compounds was performed to measure cell proliferation of Ba/F3 cells expressing different mutant types of EGFR with or without IL-3. 1st: First-round drug selection; 2nd: second-round drug selection; 3rd: third-round drug selection. LT: <t>L858R/T790M;</t> LTC: <t>L858R/T790M/C797S.</t> #: The drug was ineffective; *: the drug did not dissolve; NA: not applicable. C A high-throughput screening assay of ~125,000 compounds was performed to measure cell proliferation in EGFR-TKI resistant Ba/F3 cells expressing mutant EGFR variants. D Cells were treated with abemaciclib at the indicated concentration for 72 hours. Cell viability was analyzed using the MTS assay, and the IC50 values were comparable (on the right). The error bars represent the means ± SDs; n =3. Ba/F3 EGFR-LTC ( E ) or Ba/F3 EGFR DTC cells ( F ) were treated with abemaciclib in the absence or presence of IL-3 at the indicated concentration for 72 hours, and cell viability was analyzed using the MTS assay. G EGFR-LTC cells were treated with brigatinib in the absence or presence of IL-3 at the indicated concentration for 72 hours, and cell viability was analyzed using the MTS assay. EGFR-LT cells were treated with paclitaxel ( H ), cisplatin ( I ), and osimertinib ( J ) in the absence or presence of IL-3 at the indicated concentration for 72 hours, and cell viability was analyzed using the MTS assay. K The proportions of H1975-LTC cells in the sub-G1 phase were determined after abemaciclib or osimertinib treatment. L Apoptosis assays were performed in H1975-LTC cells treated with the pancaspase inhibitor Z-VAD-FMK at the indicated concentration for 72 hours. M H1975-LTC cells were treated with the indicated concentration of abemaciclib for 48 hours, after which the cell lysates were harvested. Protein extracts were immunoblotted with the indicated antibodies. β-Actin served as a loading control in all the Western blotting panels
    Human Angiotensin Converting Enzyme, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+protein/Recombinant+Human+ACE+Protein%2C+CF/pmc13764097-645-3-28
    Average 93 stars, based on 1 article reviews
    human angiotensin converting enzyme - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    93
    R&D Systems neprilysin
    High-throughput screening identifies abemaciclib as a selective suppressor of osimertinib-resistant mutant <t>EGFR</t> signaling. A Schematic overview of the drug-screening protocol for the EGFR-LTC inhibitor abemaciclib. B A high-throughput screening assay of ~125,000 compounds was performed to measure cell proliferation of Ba/F3 cells expressing different mutant types of EGFR with or without IL-3. 1st: First-round drug selection; 2nd: second-round drug selection; 3rd: third-round drug selection. LT: <t>L858R/T790M;</t> LTC: <t>L858R/T790M/C797S.</t> #: The drug was ineffective; *: the drug did not dissolve; NA: not applicable. C A high-throughput screening assay of ~125,000 compounds was performed to measure cell proliferation in EGFR-TKI resistant Ba/F3 cells expressing mutant EGFR variants. D Cells were treated with abemaciclib at the indicated concentration for 72 hours. Cell viability was analyzed using the MTS assay, and the IC50 values were comparable (on the right). The error bars represent the means ± SDs; n =3. Ba/F3 EGFR-LTC ( E ) or Ba/F3 EGFR DTC cells ( F ) were treated with abemaciclib in the absence or presence of IL-3 at the indicated concentration for 72 hours, and cell viability was analyzed using the MTS assay. G EGFR-LTC cells were treated with brigatinib in the absence or presence of IL-3 at the indicated concentration for 72 hours, and cell viability was analyzed using the MTS assay. EGFR-LT cells were treated with paclitaxel ( H ), cisplatin ( I ), and osimertinib ( J ) in the absence or presence of IL-3 at the indicated concentration for 72 hours, and cell viability was analyzed using the MTS assay. K The proportions of H1975-LTC cells in the sub-G1 phase were determined after abemaciclib or osimertinib treatment. L Apoptosis assays were performed in H1975-LTC cells treated with the pancaspase inhibitor Z-VAD-FMK at the indicated concentration for 72 hours. M H1975-LTC cells were treated with the indicated concentration of abemaciclib for 48 hours, after which the cell lysates were harvested. Protein extracts were immunoblotted with the indicated antibodies. β-Actin served as a loading control in all the Western blotting panels
    Neprilysin, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+protein/Recombinant+Human+Neprilysin+(CHO-expressed)+Protein%2C+CF/pmc13764097-645-20-28
    Average 93 stars, based on 1 article reviews
    neprilysin - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    95
    R&D Systems angiotensin converting enzyme 2 ace2
    The effect of 7g .HCl on the activity of peptidases closely related to Nln. Concentration-response curves of the Nln-related zinc-metallopeptidases A) TOP, B) NEP, C) ACE and D) <t>ACE2</t> activity in the presence of 7g (0.1 to 300 μM). Enzyme activity was monitored by the hydrolysis of fluorogenic substrates described in the Methods. Basal activity of all enzymes corresponds to 100% on the vertical axis and is the same as vehicle control (n = 4). An additional one-way ANOVA followed by Dunnett’s multiple comparisons test was conducted to determine the statistical significance of 7g .HCl’s effect on ACE2 activity (13% activation at 100 μM, 28% activation at 300 μM; ***P < .001 compared with basal activity).
    Angiotensin Converting Enzyme 2 Ace2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+protein/Recombinant+Human+ACE-2+Protein%2C+CF/pmc13764097-645-11-28
    Average 95 stars, based on 1 article reviews
    angiotensin converting enzyme 2 ace2 - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    96
    R&D Systems human m csf
    ( A ) UMAP plot of myeloid cells from duodenal tissues of our patients and public control datasets with duodenum and MLNs of unborn and healthy adults ( – ). A total of 21,662 single cells are contained in the plot. ( B ) Comparison of distributions among the myeloid cells with categorized norovirus RNA levels and the ratio of cells with high levels of viral RNA to total cells of each myeloid cell type. The UMAP plot includes a total of 292 cells with high viral RNA, 205 cells with low viral RNA, and 21,165 cells with undetectable viral RNA. ( C ) Comparison of marker gene expressions of M2 macrophages among the myeloid cell types in the duodenum and MLNs. The marker genes were selected from later bulk RNA-seq of in <t>vitro</t> <t>cultured</t> M2 macrophages differentiated from monocytes in PBMCs by <t>M-CSF</t> plus dexamethasone. The average expression level of each myeloid cell type at the single-cell level was calculated and displayed in UMAP and violin plots. ( D ) Volcano plot displaying differential gene expressions between the myeloid cells with high and undetectable viral RNAs. Cutoff values; log2(fold change) = 1.0, P = 0.01. ( E ) Violin plots to compare the mRNA levels of FUCA1 , CXCL9 , PLA2G7 , and IL2RA among the myeloid cells with high and low norovirus RNA levels and undetectable viral RNA. Wilcoxon test was performed for the statistics.
    Human M Csf, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+protein/Recombinant+Human+M-CSF+Protein/pmc13754023-381-5-9
    Average 96 stars, based on 1 article reviews
    human m csf - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    96
    R&D Systems human gm csf
    ( A ) Schematic protocol for differentiation of PBMC-derived monocytes from secretor-negative or -positive donor with <t>M-CSF</t> (50 ng/ml; M0 <t>macrophage),</t> <t>GM-CSF</t> (50 ng/ml; M1 macrophage), or M-CSF (50 ng/mL) plus dexamethasone (1 μM; M2 macrophage) for 7 days, followed by GII.4 norovirus inoculation. Created in BioRender. Y. Matsushima (2026; https://BioRender.com/go5bv1s ). ( B ) Heatmap of differential gene expression among M0, M1, and M2 macrophages at 3 hpi by bulk RNA-seq (three biological replicates/group). ( C ) Extracellular norovirus RNA levels in M0, M1, and M2 macrophages from a secretor-negative donor following GII.4[P16] inoculation (9.34 × 10 4 copies; three biological replicates per group). ( D ) Extracellular viral RNA levels at 3 hpi and 5 dpi in M0, M1, and M2 macrophages from a secretor-positive donor (four experiments). ( E ) Identification of norovirus-infected cells in M2 macrophages from a secretor-positive donor at 1 dpi by immunofluorescence assay. dsRNA, green; VP1, red; DAPI, blue. Scale bars, 10 μm. ( F ) Extracellular viral RNA levels following untreated or UV-inactivated GII.4[P16] inoculation onto M2 macrophages from a secretor-positive donor (duplicate/triplicate experiments). ( G ) Restricted replication of GII.4[P16] (9.34 × 10 4 copies) or GII.3[P21] (3.09 × 10 5 copies) in M2 macrophages (Secretor-positive donor) with or without GCDCA (500 μM; duplicate experiments). ( H ) Extracellular viral RNA levels in M2 macrophages from Pts. 1 and 2 following GII.4[P31] inoculation (3.92 × 10 5 copies). ( I ) Detection of norovirus-infected cells in M2 macrophages (Pt. 1) at 1 dpi by immunofluorescence assay. dsRNA, green; VP1, red. Scale bars, 5 μm. Viral RNA was quantified by RT-qPCR. Statistics: two-way ANOVA with Tukey’s multiple-comparisons test [(C), (D), (F), and (G)] and two-way ANOVA with uncorrected Fisher’s LSD (H). * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001.
    Human Gm Csf, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+protein/Recombinant+Human+GM-CSF+Protein/pmc13754023-381-16-20
    Average 96 stars, based on 1 article reviews
    human gm csf - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    Image Search Results


    Effects of prednisolone on macrophage polarization and regulatory T (Treg) cell induction mediated by cADSCs. (a) Representative flow cytometry plots showing cluster designation (CD) 80 and CD206 expression in CD14 + DH82 cells. Cells cultured alone under control conditions or stimulated with interleukin (IL)-4/IL-13 or lipopolysaccharide (LPS)/interferon (IFN)-γ are shown, together with DH82 cells co-cultured with cADSCs pretreated with prednisolone at the indicated concentrations (0–100 μM) under LPS/IFN-γ stimulation. (b) Quantitative analysis of macrophage subsets, defined as CD14 + CD80 + CD206 - , CD14 + CD80 − CD206 + , CD14 + CD80 + CD206 + , and CD14 + CD80 − CD206 - cells. IL-4/IL-13 stimulation was included as an M2-polarizing control, whereas LPS/IFN-γ stimulation induced M1-like polarization. (c) Representative flow cytometry plots showing CD25 and Foxp3 expression in CD4 + T cells after co-culture of PBMCs with cADSCs pretreated with prednisolone. Red boxes indicate CD25 + Foxp3 + Treg cells. (d) Quantification of CD25 + Foxp3 + Treg cells within the CD4 + T-cell population. Data are presented as mean ± SD from three independent experiments using cADSCs derived from three independent donors. * p < 0.05 vs. control or PBMCs alone; † p < 0.05 vs. LPS/IFN-γ.

    Journal: Regenerative Therapy

    Article Title: Prednisolone attenuates the immunomodulatory capacity and reshapes the functional phenotype of canine adipose-derived mesenchymal stromal cells

    doi: 10.1016/j.reth.2026.101184

    Figure Lengend Snippet: Effects of prednisolone on macrophage polarization and regulatory T (Treg) cell induction mediated by cADSCs. (a) Representative flow cytometry plots showing cluster designation (CD) 80 and CD206 expression in CD14 + DH82 cells. Cells cultured alone under control conditions or stimulated with interleukin (IL)-4/IL-13 or lipopolysaccharide (LPS)/interferon (IFN)-γ are shown, together with DH82 cells co-cultured with cADSCs pretreated with prednisolone at the indicated concentrations (0–100 μM) under LPS/IFN-γ stimulation. (b) Quantitative analysis of macrophage subsets, defined as CD14 + CD80 + CD206 - , CD14 + CD80 − CD206 + , CD14 + CD80 + CD206 + , and CD14 + CD80 − CD206 - cells. IL-4/IL-13 stimulation was included as an M2-polarizing control, whereas LPS/IFN-γ stimulation induced M1-like polarization. (c) Representative flow cytometry plots showing CD25 and Foxp3 expression in CD4 + T cells after co-culture of PBMCs with cADSCs pretreated with prednisolone. Red boxes indicate CD25 + Foxp3 + Treg cells. (d) Quantification of CD25 + Foxp3 + Treg cells within the CD4 + T-cell population. Data are presented as mean ± SD from three independent experiments using cADSCs derived from three independent donors. * p < 0.05 vs. control or PBMCs alone; † p < 0.05 vs. LPS/IFN-γ.

    Article Snippet: To induce macrophage polarization, either a combination of 50 ng/mL lipopolysaccharide (LPS; Sigma-Aldrich) and 20 ng/mL recombinant canine interferon (IFN)-γ (R&D Systems), or a combination of 40 ng/mL recombinant human interleukin (IL)-4 (Thermo Fisher Scientific) and 40 ng/mL recombinant human IL-13 (Thermo Fisher Scientific), was added to the cultures, followed by incubation at 37 °C in 5% CO 2 for 72 h. At the end of the co-culture period, cells were collected, washed with FACS buffer, and incubated on ice with canine Fc receptor binding inhibitor.

    Techniques: Flow Cytometry, Expressing, Cell Culture, Control, Analysis, Co-culture Assay, Derivative Assay

    Exploring single gastruloid heterogeneity. (a) Shown are sequential bright-field (upper row) and fluorescence (lower row) images using widefield microscopy of a single microraft possessing hPSCs expressing a SOX2-mCitrine reporter. BMP4 was added to the cultures at time 0 h to initiate gastruloid formation. Scale bars, 100 μ m. (b) Schematic of the live time-series imaging and end point RNA-seq workflow. SOX2 dynamics and gene expression profiles of single gastruloids were acquired. 16D latent representations were formed from individual YX slices of imaging time-series (widefield microscopy) of each gastruloid and visualized via UMAP dimensionality reduction. Gastruloid heterogeneity across and within experimental batches was assessed using the image-based latent representations and sequence-based gene expression profiles.

    Journal: APL Bioengineering

    Article Title: Heterogeneous patterning behavior emerges from human stem cell-based embryo model

    doi: 10.1063/5.0329616

    Figure Lengend Snippet: Exploring single gastruloid heterogeneity. (a) Shown are sequential bright-field (upper row) and fluorescence (lower row) images using widefield microscopy of a single microraft possessing hPSCs expressing a SOX2-mCitrine reporter. BMP4 was added to the cultures at time 0 h to initiate gastruloid formation. Scale bars, 100 μ m. (b) Schematic of the live time-series imaging and end point RNA-seq workflow. SOX2 dynamics and gene expression profiles of single gastruloids were acquired. 16D latent representations were formed from individual YX slices of imaging time-series (widefield microscopy) of each gastruloid and visualized via UMAP dimensionality reduction. Gastruloid heterogeneity across and within experimental batches was assessed using the image-based latent representations and sequence-based gene expression profiles.

    Article Snippet: The cells were allowed to attach onto the array at 37 °C and 5% CO 2 for 2 h. Subsequently, the array was placed into mTeSR Plus containing 50 ng/mL bone morphogenetic protein 4 (BMP4) (#314-BP-010, R&D Systems, Minneapolis, MN), and the micropatterned cells were cultured at 37 °C and 5% CO 2 for 48 h. Three frozen aliquots (A, B, and C) of the same RUES2 cell line subculture were thawed to form gastruloids on the micropatterned microrafts ( ).

    Techniques: Fluorescence, Widefield, Microscopy, Expressing, Imaging, RNA Sequencing, Gene Expression, Sequencing

    High-throughput screening identifies abemaciclib as a selective suppressor of osimertinib-resistant mutant EGFR signaling. A Schematic overview of the drug-screening protocol for the EGFR-LTC inhibitor abemaciclib. B A high-throughput screening assay of ~125,000 compounds was performed to measure cell proliferation of Ba/F3 cells expressing different mutant types of EGFR with or without IL-3. 1st: First-round drug selection; 2nd: second-round drug selection; 3rd: third-round drug selection. LT: L858R/T790M; LTC: L858R/T790M/C797S. #: The drug was ineffective; *: the drug did not dissolve; NA: not applicable. C A high-throughput screening assay of ~125,000 compounds was performed to measure cell proliferation in EGFR-TKI resistant Ba/F3 cells expressing mutant EGFR variants. D Cells were treated with abemaciclib at the indicated concentration for 72 hours. Cell viability was analyzed using the MTS assay, and the IC50 values were comparable (on the right). The error bars represent the means ± SDs; n =3. Ba/F3 EGFR-LTC ( E ) or Ba/F3 EGFR DTC cells ( F ) were treated with abemaciclib in the absence or presence of IL-3 at the indicated concentration for 72 hours, and cell viability was analyzed using the MTS assay. G EGFR-LTC cells were treated with brigatinib in the absence or presence of IL-3 at the indicated concentration for 72 hours, and cell viability was analyzed using the MTS assay. EGFR-LT cells were treated with paclitaxel ( H ), cisplatin ( I ), and osimertinib ( J ) in the absence or presence of IL-3 at the indicated concentration for 72 hours, and cell viability was analyzed using the MTS assay. K The proportions of H1975-LTC cells in the sub-G1 phase were determined after abemaciclib or osimertinib treatment. L Apoptosis assays were performed in H1975-LTC cells treated with the pancaspase inhibitor Z-VAD-FMK at the indicated concentration for 72 hours. M H1975-LTC cells were treated with the indicated concentration of abemaciclib for 48 hours, after which the cell lysates were harvested. Protein extracts were immunoblotted with the indicated antibodies. β-Actin served as a loading control in all the Western blotting panels

    Journal: Journal of Biomedical Science

    Article Title: Repurposing of abemaciclib to overcome C797S-mediated osimertinib resistance in EGFR-mutant lung adenocarcinoma

    doi: 10.1186/s12929-026-01297-0

    Figure Lengend Snippet: High-throughput screening identifies abemaciclib as a selective suppressor of osimertinib-resistant mutant EGFR signaling. A Schematic overview of the drug-screening protocol for the EGFR-LTC inhibitor abemaciclib. B A high-throughput screening assay of ~125,000 compounds was performed to measure cell proliferation of Ba/F3 cells expressing different mutant types of EGFR with or without IL-3. 1st: First-round drug selection; 2nd: second-round drug selection; 3rd: third-round drug selection. LT: L858R/T790M; LTC: L858R/T790M/C797S. #: The drug was ineffective; *: the drug did not dissolve; NA: not applicable. C A high-throughput screening assay of ~125,000 compounds was performed to measure cell proliferation in EGFR-TKI resistant Ba/F3 cells expressing mutant EGFR variants. D Cells were treated with abemaciclib at the indicated concentration for 72 hours. Cell viability was analyzed using the MTS assay, and the IC50 values were comparable (on the right). The error bars represent the means ± SDs; n =3. Ba/F3 EGFR-LTC ( E ) or Ba/F3 EGFR DTC cells ( F ) were treated with abemaciclib in the absence or presence of IL-3 at the indicated concentration for 72 hours, and cell viability was analyzed using the MTS assay. G EGFR-LTC cells were treated with brigatinib in the absence or presence of IL-3 at the indicated concentration for 72 hours, and cell viability was analyzed using the MTS assay. EGFR-LT cells were treated with paclitaxel ( H ), cisplatin ( I ), and osimertinib ( J ) in the absence or presence of IL-3 at the indicated concentration for 72 hours, and cell viability was analyzed using the MTS assay. K The proportions of H1975-LTC cells in the sub-G1 phase were determined after abemaciclib or osimertinib treatment. L Apoptosis assays were performed in H1975-LTC cells treated with the pancaspase inhibitor Z-VAD-FMK at the indicated concentration for 72 hours. M H1975-LTC cells were treated with the indicated concentration of abemaciclib for 48 hours, after which the cell lysates were harvested. Protein extracts were immunoblotted with the indicated antibodies. β-Actin served as a loading control in all the Western blotting panels

    Article Snippet: Briefly, 500 ng of recombinant EGFR protein (EGFR WT, Cat. 40187; EGFR L858R/T790M/C797S, Cat. 40351, BPS, Bioscience), 5 μg of substrate (poly (Glu-Tyr), P 0275, Sigma) and 250 picomole of ATP in EGRF kinase buffer (50 mM HEPES (pH 7.5), 10 mM MgCl 2 , 1 mM EGTA, 0.01% Brij-35) supplemented with vehicle or inhibitors were added in a total volume of 25 μl at room temperature for one hour.

    Techniques: High Throughput Screening Assay, Mutagenesis, Drug discovery, Expressing, Selection, Concentration Assay, MTS Assay, Control, Western Blot, HTS Assay

    Abemaciclib suppresses phosphorylation of osimertinib-resistant EGFR triple mutants in vitro. Effect of abemaciclib on phosphorylated EGFR levels. A Immunoprecipitation (IP) and Western blotting were performed in H1975-LTC cells treated with abemaciclib for 6 hours, and the levels of phosphorylated EGFR were analyzed. β-actin served as a loading control. Effects of abemaciclib or osimertinib on phosphorylated EGFR levels. After 6 hours of abemaciclib incubation, phosphorylated EGFR levels were determined in Ba/F3-DT ( B ), Ba/F3-DTC ( C ), Ba/F3-LTC ( D ), H1975-LT ( E ), H1975-LTC ( F ) cells and phosphorylated S6 levels were determined in H1975-LTC ( F ) by Western blotting. Quantitative plots are shown on the right ( C and D ) or below ( F ) and each experiment was performed in three independent replicates, and the values for each treatment group were normalized to the corresponding control within the same experiment. Each treatment group was compared with the control using a two-tailed one-sample Student‘s t-test. Multiple comparisons were accounted for using the Benjamini-Hochberg (BH) false discovery rate (FDR) correction and an adjusted P value<0.05 was considered statistically significant. G The levels of phosphorylated EGFR were examined in BaF3-Del 19, BaF3-DT, BaF3-DTC, BaF3-L858R, BaF3-LT, BaF3-LTC cells by Western blotting, and quantitative plots are shown below. The error bars represent the means ± SDs; n =3

    Journal: Journal of Biomedical Science

    Article Title: Repurposing of abemaciclib to overcome C797S-mediated osimertinib resistance in EGFR-mutant lung adenocarcinoma

    doi: 10.1186/s12929-026-01297-0

    Figure Lengend Snippet: Abemaciclib suppresses phosphorylation of osimertinib-resistant EGFR triple mutants in vitro. Effect of abemaciclib on phosphorylated EGFR levels. A Immunoprecipitation (IP) and Western blotting were performed in H1975-LTC cells treated with abemaciclib for 6 hours, and the levels of phosphorylated EGFR were analyzed. β-actin served as a loading control. Effects of abemaciclib or osimertinib on phosphorylated EGFR levels. After 6 hours of abemaciclib incubation, phosphorylated EGFR levels were determined in Ba/F3-DT ( B ), Ba/F3-DTC ( C ), Ba/F3-LTC ( D ), H1975-LT ( E ), H1975-LTC ( F ) cells and phosphorylated S6 levels were determined in H1975-LTC ( F ) by Western blotting. Quantitative plots are shown on the right ( C and D ) or below ( F ) and each experiment was performed in three independent replicates, and the values for each treatment group were normalized to the corresponding control within the same experiment. Each treatment group was compared with the control using a two-tailed one-sample Student‘s t-test. Multiple comparisons were accounted for using the Benjamini-Hochberg (BH) false discovery rate (FDR) correction and an adjusted P value<0.05 was considered statistically significant. G The levels of phosphorylated EGFR were examined in BaF3-Del 19, BaF3-DT, BaF3-DTC, BaF3-L858R, BaF3-LT, BaF3-LTC cells by Western blotting, and quantitative plots are shown below. The error bars represent the means ± SDs; n =3

    Article Snippet: Briefly, 500 ng of recombinant EGFR protein (EGFR WT, Cat. 40187; EGFR L858R/T790M/C797S, Cat. 40351, BPS, Bioscience), 5 μg of substrate (poly (Glu-Tyr), P 0275, Sigma) and 250 picomole of ATP in EGRF kinase buffer (50 mM HEPES (pH 7.5), 10 mM MgCl 2 , 1 mM EGTA, 0.01% Brij-35) supplemented with vehicle or inhibitors were added in a total volume of 25 μl at room temperature for one hour.

    Techniques: Phospho-proteomics, In Vitro, Immunoprecipitation, Western Blot, Control, Incubation, Two Tailed Test

    Abemaciclib selectively inhibits mutant EGFR and directly engages resistant EGFR variants. A An in vitro kinase assay was performed to measure the kinase activity of EGFR-WT and EGFR-LTC proteins treated with abemaciclib at the indicated concentrations. EGFR-LTC kinase activity was determined in vitro to measure the kinase activity of EGFR-LTC protein after treatment with abemaciclib, along with a relatively high concentration of ATP ( B ) or substrate ( C ). The IC50 values are presented below the chart. D An in vitro kinase assay was conducted to measure the kinase activity of the WT, L858R, LT and LTC-EGFR proteins treated with abemaciclib at the indicated concentrations. Effect of abemaciclib on phosphorylated EGFR levels in cells treated with or without EGF. The levels of phosphorylated EGFR were examined in H460 ( E ), Hop92 ( F ), H1975-LT ( G ) and H1975-LTC ( H ) cells by Western blotting. Quantitative plots are shown below. Each treatment group was compared with the EGF ligand stimulation group using a two-tailed one-sample Student's t-test. Multiple comparisons were accounted for using the Benjamini-Hochberg (BH) false discovery rate (FDR) correction and an adjusted P value < 0.05 was considered statistically significant. GAPDH served as a loading control in all the Western blotting panels. I A cellular thermal shift assay (CETSA) was performed in H1975-35 cells. H1975-35 cells were treated with DMSO or abemaciclib and subjected to the indicated temperature gradient (0–64°C). Cell lysates were analyzed by Western blotting for EGFR, CDK4, and β-actin. Band intensities were quantified by densitometry and normalized to the 0 °C condition. β-actin was used as a loading control. The binding mode of abemaciclib complexed with the EGFR L858R/T790M (PDB ID: 3IKA) ( J ) and EGFR L858R/T790M/C797S (PDB ID: 6LUB) structures ( K ) was analyzed by molecular docking. A summary table is shown ( L ). M Phosphokinase array analysis (#ARY003B; R&D Systems) was performed after treatment with abemaciclib. The bar graph showed differences of more than 2-fold between the abemaciclib-treated and control groups

    Journal: Journal of Biomedical Science

    Article Title: Repurposing of abemaciclib to overcome C797S-mediated osimertinib resistance in EGFR-mutant lung adenocarcinoma

    doi: 10.1186/s12929-026-01297-0

    Figure Lengend Snippet: Abemaciclib selectively inhibits mutant EGFR and directly engages resistant EGFR variants. A An in vitro kinase assay was performed to measure the kinase activity of EGFR-WT and EGFR-LTC proteins treated with abemaciclib at the indicated concentrations. EGFR-LTC kinase activity was determined in vitro to measure the kinase activity of EGFR-LTC protein after treatment with abemaciclib, along with a relatively high concentration of ATP ( B ) or substrate ( C ). The IC50 values are presented below the chart. D An in vitro kinase assay was conducted to measure the kinase activity of the WT, L858R, LT and LTC-EGFR proteins treated with abemaciclib at the indicated concentrations. Effect of abemaciclib on phosphorylated EGFR levels in cells treated with or without EGF. The levels of phosphorylated EGFR were examined in H460 ( E ), Hop92 ( F ), H1975-LT ( G ) and H1975-LTC ( H ) cells by Western blotting. Quantitative plots are shown below. Each treatment group was compared with the EGF ligand stimulation group using a two-tailed one-sample Student's t-test. Multiple comparisons were accounted for using the Benjamini-Hochberg (BH) false discovery rate (FDR) correction and an adjusted P value < 0.05 was considered statistically significant. GAPDH served as a loading control in all the Western blotting panels. I A cellular thermal shift assay (CETSA) was performed in H1975-35 cells. H1975-35 cells were treated with DMSO or abemaciclib and subjected to the indicated temperature gradient (0–64°C). Cell lysates were analyzed by Western blotting for EGFR, CDK4, and β-actin. Band intensities were quantified by densitometry and normalized to the 0 °C condition. β-actin was used as a loading control. The binding mode of abemaciclib complexed with the EGFR L858R/T790M (PDB ID: 3IKA) ( J ) and EGFR L858R/T790M/C797S (PDB ID: 6LUB) structures ( K ) was analyzed by molecular docking. A summary table is shown ( L ). M Phosphokinase array analysis (#ARY003B; R&D Systems) was performed after treatment with abemaciclib. The bar graph showed differences of more than 2-fold between the abemaciclib-treated and control groups

    Article Snippet: Briefly, 500 ng of recombinant EGFR protein (EGFR WT, Cat. 40187; EGFR L858R/T790M/C797S, Cat. 40351, BPS, Bioscience), 5 μg of substrate (poly (Glu-Tyr), P 0275, Sigma) and 250 picomole of ATP in EGRF kinase buffer (50 mM HEPES (pH 7.5), 10 mM MgCl 2 , 1 mM EGTA, 0.01% Brij-35) supplemented with vehicle or inhibitors were added in a total volume of 25 μl at room temperature for one hour.

    Techniques: Mutagenesis, In Vitro, Kinase Assay, Activity Assay, Concentration Assay, Western Blot, Two Tailed Test, Control, Thermal Shift Assay, Binding Assay, Docking Assay, Analysis

    Abemaciclib suppresses tumor growth in xenograft models harboring EGFR L858R/T790M/C797S mutations. A schematic representation of the experimental procedure of the animal model is shown at the top. ( A – E ) Effect of oral gavage of abemaciclib or osimertinib on tumor growth. The tumor volume was measured as described in the Materials and Methods (n = 6 mice per group). ( F–G ) After the in vivo assay was performed, the mice were sacrificed, and the net tumor weights were measured. The data are presented as the means ± SEMs. * P < 0.05, ** P < 0.01, and *** P < 0.001. H Abemaciclib decreased p-EGFR levels in H1975-LTC xenograft tumors. The protein extracts from the tumor sections were subjected to Western blotting. I Effects of abemaciclib or osimertinib oral gavage on mouse body weight. J Abemaciclib decreased p-EGFR levels in H1975-EGFR-LTC xenograft tumors. The protein extracts from the tumor sections were subjected to Western blotting

    Journal: Journal of Biomedical Science

    Article Title: Repurposing of abemaciclib to overcome C797S-mediated osimertinib resistance in EGFR-mutant lung adenocarcinoma

    doi: 10.1186/s12929-026-01297-0

    Figure Lengend Snippet: Abemaciclib suppresses tumor growth in xenograft models harboring EGFR L858R/T790M/C797S mutations. A schematic representation of the experimental procedure of the animal model is shown at the top. ( A – E ) Effect of oral gavage of abemaciclib or osimertinib on tumor growth. The tumor volume was measured as described in the Materials and Methods (n = 6 mice per group). ( F–G ) After the in vivo assay was performed, the mice were sacrificed, and the net tumor weights were measured. The data are presented as the means ± SEMs. * P < 0.05, ** P < 0.01, and *** P < 0.001. H Abemaciclib decreased p-EGFR levels in H1975-LTC xenograft tumors. The protein extracts from the tumor sections were subjected to Western blotting. I Effects of abemaciclib or osimertinib oral gavage on mouse body weight. J Abemaciclib decreased p-EGFR levels in H1975-EGFR-LTC xenograft tumors. The protein extracts from the tumor sections were subjected to Western blotting

    Article Snippet: Briefly, 500 ng of recombinant EGFR protein (EGFR WT, Cat. 40187; EGFR L858R/T790M/C797S, Cat. 40351, BPS, Bioscience), 5 μg of substrate (poly (Glu-Tyr), P 0275, Sigma) and 250 picomole of ATP in EGRF kinase buffer (50 mM HEPES (pH 7.5), 10 mM MgCl 2 , 1 mM EGTA, 0.01% Brij-35) supplemented with vehicle or inhibitors were added in a total volume of 25 μl at room temperature for one hour.

    Techniques: Xenograft Assay, Animal Model, In Vivo, Western Blot, Two Tailed Test

    Abemaciclib inhibits mutant EGFR signaling and induces apoptosis in CRISPR-engineered EGFR C797S isogenic models. H1975 and isogenic cells (H1975-12 and H1975-35) were treated with osimertinib ( A ) or abemaciclib ( B ) at the indicated concentrations for 72 hours, and cell viability was analyzed using the MTS assay. Effects of abemaciclib or osimertinib on phosphorylated EGFR levels. The levels of phosphorylated EGFR were examined in H1975-12 ( C ) and H1975-35 ( D ) cells by Western blotting and were quantified using ImageJ software. GAPDH served as a loading control. The proportions of H1975-12 ( E ) and H1975-35 ( F ) cells in the sub-G1 phase were determined after abemaciclib or osimertinib treatment. H1975-12 ( G ) and H1975-35 ( H ) cells were treated with the indicated concentrations of abemaciclib or osimertinib for 72 hours, after which the cell lysates were harvested. Protein extracts were immunoblotted with the indicated antibodies. β-Actin served as a loading control in all the Western blotting panels

    Journal: Journal of Biomedical Science

    Article Title: Repurposing of abemaciclib to overcome C797S-mediated osimertinib resistance in EGFR-mutant lung adenocarcinoma

    doi: 10.1186/s12929-026-01297-0

    Figure Lengend Snippet: Abemaciclib inhibits mutant EGFR signaling and induces apoptosis in CRISPR-engineered EGFR C797S isogenic models. H1975 and isogenic cells (H1975-12 and H1975-35) were treated with osimertinib ( A ) or abemaciclib ( B ) at the indicated concentrations for 72 hours, and cell viability was analyzed using the MTS assay. Effects of abemaciclib or osimertinib on phosphorylated EGFR levels. The levels of phosphorylated EGFR were examined in H1975-12 ( C ) and H1975-35 ( D ) cells by Western blotting and were quantified using ImageJ software. GAPDH served as a loading control. The proportions of H1975-12 ( E ) and H1975-35 ( F ) cells in the sub-G1 phase were determined after abemaciclib or osimertinib treatment. H1975-12 ( G ) and H1975-35 ( H ) cells were treated with the indicated concentrations of abemaciclib or osimertinib for 72 hours, after which the cell lysates were harvested. Protein extracts were immunoblotted with the indicated antibodies. β-Actin served as a loading control in all the Western blotting panels

    Article Snippet: Briefly, 500 ng of recombinant EGFR protein (EGFR WT, Cat. 40187; EGFR L858R/T790M/C797S, Cat. 40351, BPS, Bioscience), 5 μg of substrate (poly (Glu-Tyr), P 0275, Sigma) and 250 picomole of ATP in EGRF kinase buffer (50 mM HEPES (pH 7.5), 10 mM MgCl 2 , 1 mM EGTA, 0.01% Brij-35) supplemented with vehicle or inhibitors were added in a total volume of 25 μl at room temperature for one hour.

    Techniques: Mutagenesis, CRISPR, MTS Assay, Western Blot, Software, Control

    Abemaciclib demonstrates potent antitumor activity in EGFR C797S isogenic xenograft models. A schematic representation of the experimental procedure of the animal model is shown at the top. ( A – H ) Effect of oral gavage of abemaciclib or osimertinib on the tumor growth of the H1975 isogenic line. The tumor volume was measured as described in the Materials and Methods (n=6 mice per group). I After the in vivo assay was performed, the mice were sacrificed, and the net tumor weights were measured. The data are presented as the means ± SEMs. * P < 0.05, ** P < 0.01, and *** P < 0.001. ( J – K ) Abemaciclib decreased p-EGFR levels in H1975-LTC isogenic xenograft tumors. The protein extracts from the tumor sections were subjected to Western blotting. L Effects of oral gavage of abemaciclib and osimertinib on mouse body weight

    Journal: Journal of Biomedical Science

    Article Title: Repurposing of abemaciclib to overcome C797S-mediated osimertinib resistance in EGFR-mutant lung adenocarcinoma

    doi: 10.1186/s12929-026-01297-0

    Figure Lengend Snippet: Abemaciclib demonstrates potent antitumor activity in EGFR C797S isogenic xenograft models. A schematic representation of the experimental procedure of the animal model is shown at the top. ( A – H ) Effect of oral gavage of abemaciclib or osimertinib on the tumor growth of the H1975 isogenic line. The tumor volume was measured as described in the Materials and Methods (n=6 mice per group). I After the in vivo assay was performed, the mice were sacrificed, and the net tumor weights were measured. The data are presented as the means ± SEMs. * P < 0.05, ** P < 0.01, and *** P < 0.001. ( J – K ) Abemaciclib decreased p-EGFR levels in H1975-LTC isogenic xenograft tumors. The protein extracts from the tumor sections were subjected to Western blotting. L Effects of oral gavage of abemaciclib and osimertinib on mouse body weight

    Article Snippet: Briefly, 500 ng of recombinant EGFR protein (EGFR WT, Cat. 40187; EGFR L858R/T790M/C797S, Cat. 40351, BPS, Bioscience), 5 μg of substrate (poly (Glu-Tyr), P 0275, Sigma) and 250 picomole of ATP in EGRF kinase buffer (50 mM HEPES (pH 7.5), 10 mM MgCl 2 , 1 mM EGTA, 0.01% Brij-35) supplemented with vehicle or inhibitors were added in a total volume of 25 μl at room temperature for one hour.

    Techniques: Activity Assay, Xenograft Assay, Animal Model, In Vivo, Western Blot

    Abemaciclib inhibits tumor growth in a PDX model harboring EGFR-DTC mutations both in vitro and in vivo. Sequencing analysis of CLH206 cells, which express the EGFR Del19/T790M (+/ − : 40/60)/C797S (+/−: 60/40) mutant ( A ) or VGHT11 cells, which express the EGFR Del19/T790M (+/ − : 50/50)/C797S (+/ − : 30/70) mutant ( B ). CLH206 cells and VGHT11 were treated with osimertinib ( C ) or abemaciclib ( D ) at the indicated concentrations for 72 hours, and cell viability was analyzed using the MTS assay. E Effects of abemaciclib or osimertinib on phosphorylated EGFR levels in CLH206 cells, as determined by Western blotting. GAPDH served as a loading control. F A schematic representation of the experimental procedure of the animal model. ( G – K ) Effect of oral gavage of abemaciclib or osimertinib on the growth of CLH206 tumors. The tumor volume was measured as described in the Materials and Methods (n = 8 mice per group). ( L – M ) After the in vivo assay was performed, the mice were sacrificed, and the net tumor weights were measured. The data are presented as the means ± SEMs. * P < 0.05, ** P < 0.01, and *** P < 0.001. N Effects of oral gavage of abemaciclib or osimertinib on the body weights of the mice. The levels of ALT ( O ), AST ( P ), BUN ( Q ), and CRE ( R ) in CLH206 tumor-bearing mice treated with abemaciclib or osimertinib, excluding those in mice with hemolyzed blood, were evaluated

    Journal: Journal of Biomedical Science

    Article Title: Repurposing of abemaciclib to overcome C797S-mediated osimertinib resistance in EGFR-mutant lung adenocarcinoma

    doi: 10.1186/s12929-026-01297-0

    Figure Lengend Snippet: Abemaciclib inhibits tumor growth in a PDX model harboring EGFR-DTC mutations both in vitro and in vivo. Sequencing analysis of CLH206 cells, which express the EGFR Del19/T790M (+/ − : 40/60)/C797S (+/−: 60/40) mutant ( A ) or VGHT11 cells, which express the EGFR Del19/T790M (+/ − : 50/50)/C797S (+/ − : 30/70) mutant ( B ). CLH206 cells and VGHT11 were treated with osimertinib ( C ) or abemaciclib ( D ) at the indicated concentrations for 72 hours, and cell viability was analyzed using the MTS assay. E Effects of abemaciclib or osimertinib on phosphorylated EGFR levels in CLH206 cells, as determined by Western blotting. GAPDH served as a loading control. F A schematic representation of the experimental procedure of the animal model. ( G – K ) Effect of oral gavage of abemaciclib or osimertinib on the growth of CLH206 tumors. The tumor volume was measured as described in the Materials and Methods (n = 8 mice per group). ( L – M ) After the in vivo assay was performed, the mice were sacrificed, and the net tumor weights were measured. The data are presented as the means ± SEMs. * P < 0.05, ** P < 0.01, and *** P < 0.001. N Effects of oral gavage of abemaciclib or osimertinib on the body weights of the mice. The levels of ALT ( O ), AST ( P ), BUN ( Q ), and CRE ( R ) in CLH206 tumor-bearing mice treated with abemaciclib or osimertinib, excluding those in mice with hemolyzed blood, were evaluated

    Article Snippet: Briefly, 500 ng of recombinant EGFR protein (EGFR WT, Cat. 40187; EGFR L858R/T790M/C797S, Cat. 40351, BPS, Bioscience), 5 μg of substrate (poly (Glu-Tyr), P 0275, Sigma) and 250 picomole of ATP in EGRF kinase buffer (50 mM HEPES (pH 7.5), 10 mM MgCl 2 , 1 mM EGTA, 0.01% Brij-35) supplemented with vehicle or inhibitors were added in a total volume of 25 μl at room temperature for one hour.

    Techniques: In Vitro, In Vivo, Sequencing, Analysis, Mutagenesis, MTS Assay, Western Blot, Control, Animal Model

    Proposed model of mutation-selective suppression of C797S-mutant EGFR by abemaciclib. Acquisition of the EGFR C797S mutation confers resistance to osimertinib and sustains oncogenic EGFR signaling. Through high-throughput screening, abemaciclib was identified as a potent suppressor of C797S-containing EGFR variants. Biochemical assays, CETSA analyses, and molecular docking studies support direct engagement of mutant EGFR by abemaciclib. Inhibition of mutant EGFR signaling results in reduced EGFR phosphorylation, induction of apoptotic cell death, and suppression of tumor growth in CRISPR-engineered and patient-derived xenograft models of osimertinib-resistant EGFR-mutant NSCLC. This schematic summarizes the proposed mechanism and therapeutic implications of abemaciclib in overcoming EGFR C797S-mediated osimertinib resistance. The model is based on experimental observations and does not represent an experimentally resolved binding structure

    Journal: Journal of Biomedical Science

    Article Title: Repurposing of abemaciclib to overcome C797S-mediated osimertinib resistance in EGFR-mutant lung adenocarcinoma

    doi: 10.1186/s12929-026-01297-0

    Figure Lengend Snippet: Proposed model of mutation-selective suppression of C797S-mutant EGFR by abemaciclib. Acquisition of the EGFR C797S mutation confers resistance to osimertinib and sustains oncogenic EGFR signaling. Through high-throughput screening, abemaciclib was identified as a potent suppressor of C797S-containing EGFR variants. Biochemical assays, CETSA analyses, and molecular docking studies support direct engagement of mutant EGFR by abemaciclib. Inhibition of mutant EGFR signaling results in reduced EGFR phosphorylation, induction of apoptotic cell death, and suppression of tumor growth in CRISPR-engineered and patient-derived xenograft models of osimertinib-resistant EGFR-mutant NSCLC. This schematic summarizes the proposed mechanism and therapeutic implications of abemaciclib in overcoming EGFR C797S-mediated osimertinib resistance. The model is based on experimental observations and does not represent an experimentally resolved binding structure

    Article Snippet: Briefly, 500 ng of recombinant EGFR protein (EGFR WT, Cat. 40187; EGFR L858R/T790M/C797S, Cat. 40351, BPS, Bioscience), 5 μg of substrate (poly (Glu-Tyr), P 0275, Sigma) and 250 picomole of ATP in EGRF kinase buffer (50 mM HEPES (pH 7.5), 10 mM MgCl 2 , 1 mM EGTA, 0.01% Brij-35) supplemented with vehicle or inhibitors were added in a total volume of 25 μl at room temperature for one hour.

    Techniques: Mutagenesis, High Throughput Screening Assay, Docking Assay, Inhibition, Phospho-proteomics, CRISPR, Derivative Assay, Xenograft Assay, Binding Assay

    The effect of 7g .HCl on the activity of peptidases closely related to Nln. Concentration-response curves of the Nln-related zinc-metallopeptidases A) TOP, B) NEP, C) ACE and D) ACE2 activity in the presence of 7g (0.1 to 300 μM). Enzyme activity was monitored by the hydrolysis of fluorogenic substrates described in the Methods. Basal activity of all enzymes corresponds to 100% on the vertical axis and is the same as vehicle control (n = 4). An additional one-way ANOVA followed by Dunnett’s multiple comparisons test was conducted to determine the statistical significance of 7g .HCl’s effect on ACE2 activity (13% activation at 100 μM, 28% activation at 300 μM; ***P < .001 compared with basal activity).

    Journal: Journal of medicinal chemistry

    Article Title: Discovery of Neurolysin Activators with Preclinical Efficacy in an Ischemic Stroke Model

    doi: 10.1021/acs.jmedchem.6c02108

    Figure Lengend Snippet: The effect of 7g .HCl on the activity of peptidases closely related to Nln. Concentration-response curves of the Nln-related zinc-metallopeptidases A) TOP, B) NEP, C) ACE and D) ACE2 activity in the presence of 7g (0.1 to 300 μM). Enzyme activity was monitored by the hydrolysis of fluorogenic substrates described in the Methods. Basal activity of all enzymes corresponds to 100% on the vertical axis and is the same as vehicle control (n = 4). An additional one-way ANOVA followed by Dunnett’s multiple comparisons test was conducted to determine the statistical significance of 7g .HCl’s effect on ACE2 activity (13% activation at 100 μM, 28% activation at 300 μM; ***P < .001 compared with basal activity).

    Article Snippet: 36 , 37 Human angiotensin converting enzyme (ACE; product # 929-ZN), angiotensin converting enzyme 2 (ACE2) (product # 933-ZN), and neprilysin (NEP; product # 1182-ZNC) were obtained from R&D Systems (Minneapolis, MN).

    Techniques: Activity Assay, Concentration Assay, Control, Activation Assay

    ( A ) UMAP plot of myeloid cells from duodenal tissues of our patients and public control datasets with duodenum and MLNs of unborn and healthy adults ( – ). A total of 21,662 single cells are contained in the plot. ( B ) Comparison of distributions among the myeloid cells with categorized norovirus RNA levels and the ratio of cells with high levels of viral RNA to total cells of each myeloid cell type. The UMAP plot includes a total of 292 cells with high viral RNA, 205 cells with low viral RNA, and 21,165 cells with undetectable viral RNA. ( C ) Comparison of marker gene expressions of M2 macrophages among the myeloid cell types in the duodenum and MLNs. The marker genes were selected from later bulk RNA-seq of in vitro cultured M2 macrophages differentiated from monocytes in PBMCs by M-CSF plus dexamethasone. The average expression level of each myeloid cell type at the single-cell level was calculated and displayed in UMAP and violin plots. ( D ) Volcano plot displaying differential gene expressions between the myeloid cells with high and undetectable viral RNAs. Cutoff values; log2(fold change) = 1.0, P = 0.01. ( E ) Violin plots to compare the mRNA levels of FUCA1 , CXCL9 , PLA2G7 , and IL2RA among the myeloid cells with high and low norovirus RNA levels and undetectable viral RNA. Wilcoxon test was performed for the statistics.

    Journal: Science Advances

    Article Title: Single-cell profiling of the duodenum during chronic human norovirus infection

    doi: 10.1126/sciadv.aej2676

    Figure Lengend Snippet: ( A ) UMAP plot of myeloid cells from duodenal tissues of our patients and public control datasets with duodenum and MLNs of unborn and healthy adults ( – ). A total of 21,662 single cells are contained in the plot. ( B ) Comparison of distributions among the myeloid cells with categorized norovirus RNA levels and the ratio of cells with high levels of viral RNA to total cells of each myeloid cell type. The UMAP plot includes a total of 292 cells with high viral RNA, 205 cells with low viral RNA, and 21,165 cells with undetectable viral RNA. ( C ) Comparison of marker gene expressions of M2 macrophages among the myeloid cell types in the duodenum and MLNs. The marker genes were selected from later bulk RNA-seq of in vitro cultured M2 macrophages differentiated from monocytes in PBMCs by M-CSF plus dexamethasone. The average expression level of each myeloid cell type at the single-cell level was calculated and displayed in UMAP and violin plots. ( D ) Volcano plot displaying differential gene expressions between the myeloid cells with high and undetectable viral RNAs. Cutoff values; log2(fold change) = 1.0, P = 0.01. ( E ) Violin plots to compare the mRNA levels of FUCA1 , CXCL9 , PLA2G7 , and IL2RA among the myeloid cells with high and low norovirus RNA levels and undetectable viral RNA. Wilcoxon test was performed for the statistics.

    Article Snippet: The cells were cultured with human M-CSF (50 ng/ml; R&D system, catalog no. 216-MC, M0 macrophages), human GM-CSF (50 ng/ml; R&D system, catalog no. 215-GM, M1 macrophages) or human M-CSF (50 ng/ml) plus dexamethasone (1 μM; Sigma-Aldrich, catalog no. D2915, M2 macrophages) in RPMI1640 (Thermo Fisher Scientific, catalog no. 11875-093) medium supplemented with 10% FBS and penicillin (100 U/ml) and streptomycin (100 μg/ml) in a 96-well culture plate ( , , ).

    Techniques: Control, Comparison, Marker, RNA Sequencing, In Vitro, Cell Culture, Expressing, Single Cell, Gene Expression, Significance Assay

    ( A ) Schematic protocol for differentiation of PBMC-derived monocytes from secretor-negative or -positive donor with M-CSF (50 ng/ml; M0 macrophage), GM-CSF (50 ng/ml; M1 macrophage), or M-CSF (50 ng/mL) plus dexamethasone (1 μM; M2 macrophage) for 7 days, followed by GII.4 norovirus inoculation. Created in BioRender. Y. Matsushima (2026; https://BioRender.com/go5bv1s ). ( B ) Heatmap of differential gene expression among M0, M1, and M2 macrophages at 3 hpi by bulk RNA-seq (three biological replicates/group). ( C ) Extracellular norovirus RNA levels in M0, M1, and M2 macrophages from a secretor-negative donor following GII.4[P16] inoculation (9.34 × 10 4 copies; three biological replicates per group). ( D ) Extracellular viral RNA levels at 3 hpi and 5 dpi in M0, M1, and M2 macrophages from a secretor-positive donor (four experiments). ( E ) Identification of norovirus-infected cells in M2 macrophages from a secretor-positive donor at 1 dpi by immunofluorescence assay. dsRNA, green; VP1, red; DAPI, blue. Scale bars, 10 μm. ( F ) Extracellular viral RNA levels following untreated or UV-inactivated GII.4[P16] inoculation onto M2 macrophages from a secretor-positive donor (duplicate/triplicate experiments). ( G ) Restricted replication of GII.4[P16] (9.34 × 10 4 copies) or GII.3[P21] (3.09 × 10 5 copies) in M2 macrophages (Secretor-positive donor) with or without GCDCA (500 μM; duplicate experiments). ( H ) Extracellular viral RNA levels in M2 macrophages from Pts. 1 and 2 following GII.4[P31] inoculation (3.92 × 10 5 copies). ( I ) Detection of norovirus-infected cells in M2 macrophages (Pt. 1) at 1 dpi by immunofluorescence assay. dsRNA, green; VP1, red. Scale bars, 5 μm. Viral RNA was quantified by RT-qPCR. Statistics: two-way ANOVA with Tukey’s multiple-comparisons test [(C), (D), (F), and (G)] and two-way ANOVA with uncorrected Fisher’s LSD (H). * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001.

    Journal: Science Advances

    Article Title: Single-cell profiling of the duodenum during chronic human norovirus infection

    doi: 10.1126/sciadv.aej2676

    Figure Lengend Snippet: ( A ) Schematic protocol for differentiation of PBMC-derived monocytes from secretor-negative or -positive donor with M-CSF (50 ng/ml; M0 macrophage), GM-CSF (50 ng/ml; M1 macrophage), or M-CSF (50 ng/mL) plus dexamethasone (1 μM; M2 macrophage) for 7 days, followed by GII.4 norovirus inoculation. Created in BioRender. Y. Matsushima (2026; https://BioRender.com/go5bv1s ). ( B ) Heatmap of differential gene expression among M0, M1, and M2 macrophages at 3 hpi by bulk RNA-seq (three biological replicates/group). ( C ) Extracellular norovirus RNA levels in M0, M1, and M2 macrophages from a secretor-negative donor following GII.4[P16] inoculation (9.34 × 10 4 copies; three biological replicates per group). ( D ) Extracellular viral RNA levels at 3 hpi and 5 dpi in M0, M1, and M2 macrophages from a secretor-positive donor (four experiments). ( E ) Identification of norovirus-infected cells in M2 macrophages from a secretor-positive donor at 1 dpi by immunofluorescence assay. dsRNA, green; VP1, red; DAPI, blue. Scale bars, 10 μm. ( F ) Extracellular viral RNA levels following untreated or UV-inactivated GII.4[P16] inoculation onto M2 macrophages from a secretor-positive donor (duplicate/triplicate experiments). ( G ) Restricted replication of GII.4[P16] (9.34 × 10 4 copies) or GII.3[P21] (3.09 × 10 5 copies) in M2 macrophages (Secretor-positive donor) with or without GCDCA (500 μM; duplicate experiments). ( H ) Extracellular viral RNA levels in M2 macrophages from Pts. 1 and 2 following GII.4[P31] inoculation (3.92 × 10 5 copies). ( I ) Detection of norovirus-infected cells in M2 macrophages (Pt. 1) at 1 dpi by immunofluorescence assay. dsRNA, green; VP1, red. Scale bars, 5 μm. Viral RNA was quantified by RT-qPCR. Statistics: two-way ANOVA with Tukey’s multiple-comparisons test [(C), (D), (F), and (G)] and two-way ANOVA with uncorrected Fisher’s LSD (H). * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001.

    Article Snippet: The cells were cultured with human M-CSF (50 ng/ml; R&D system, catalog no. 216-MC, M0 macrophages), human GM-CSF (50 ng/ml; R&D system, catalog no. 215-GM, M1 macrophages) or human M-CSF (50 ng/ml) plus dexamethasone (1 μM; Sigma-Aldrich, catalog no. D2915, M2 macrophages) in RPMI1640 (Thermo Fisher Scientific, catalog no. 11875-093) medium supplemented with 10% FBS and penicillin (100 U/ml) and streptomycin (100 μg/ml) in a 96-well culture plate ( , , ).

    Techniques: Derivative Assay, Gene Expression, RNA Sequencing, Infection, Immunofluorescence, Quantitative RT-PCR

    ( A ) Schematic protocol for differentiation of PBMC-derived monocytes from secretor-negative or -positive donor with M-CSF (50 ng/ml; M0 macrophage), GM-CSF (50 ng/ml; M1 macrophage), or M-CSF (50 ng/mL) plus dexamethasone (1 μM; M2 macrophage) for 7 days, followed by GII.4 norovirus inoculation. Created in BioRender. Y. Matsushima (2026; https://BioRender.com/go5bv1s ). ( B ) Heatmap of differential gene expression among M0, M1, and M2 macrophages at 3 hpi by bulk RNA-seq (three biological replicates/group). ( C ) Extracellular norovirus RNA levels in M0, M1, and M2 macrophages from a secretor-negative donor following GII.4[P16] inoculation (9.34 × 10 4 copies; three biological replicates per group). ( D ) Extracellular viral RNA levels at 3 hpi and 5 dpi in M0, M1, and M2 macrophages from a secretor-positive donor (four experiments). ( E ) Identification of norovirus-infected cells in M2 macrophages from a secretor-positive donor at 1 dpi by immunofluorescence assay. dsRNA, green; VP1, red; DAPI, blue. Scale bars, 10 μm. ( F ) Extracellular viral RNA levels following untreated or UV-inactivated GII.4[P16] inoculation onto M2 macrophages from a secretor-positive donor (duplicate/triplicate experiments). ( G ) Restricted replication of GII.4[P16] (9.34 × 10 4 copies) or GII.3[P21] (3.09 × 10 5 copies) in M2 macrophages (Secretor-positive donor) with or without GCDCA (500 μM; duplicate experiments). ( H ) Extracellular viral RNA levels in M2 macrophages from Pts. 1 and 2 following GII.4[P31] inoculation (3.92 × 10 5 copies). ( I ) Detection of norovirus-infected cells in M2 macrophages (Pt. 1) at 1 dpi by immunofluorescence assay. dsRNA, green; VP1, red. Scale bars, 5 μm. Viral RNA was quantified by RT-qPCR. Statistics: two-way ANOVA with Tukey’s multiple-comparisons test [(C), (D), (F), and (G)] and two-way ANOVA with uncorrected Fisher’s LSD (H). * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001.

    Journal: Science Advances

    Article Title: Single-cell profiling of the duodenum during chronic human norovirus infection

    doi: 10.1126/sciadv.aej2676

    Figure Lengend Snippet: ( A ) Schematic protocol for differentiation of PBMC-derived monocytes from secretor-negative or -positive donor with M-CSF (50 ng/ml; M0 macrophage), GM-CSF (50 ng/ml; M1 macrophage), or M-CSF (50 ng/mL) plus dexamethasone (1 μM; M2 macrophage) for 7 days, followed by GII.4 norovirus inoculation. Created in BioRender. Y. Matsushima (2026; https://BioRender.com/go5bv1s ). ( B ) Heatmap of differential gene expression among M0, M1, and M2 macrophages at 3 hpi by bulk RNA-seq (three biological replicates/group). ( C ) Extracellular norovirus RNA levels in M0, M1, and M2 macrophages from a secretor-negative donor following GII.4[P16] inoculation (9.34 × 10 4 copies; three biological replicates per group). ( D ) Extracellular viral RNA levels at 3 hpi and 5 dpi in M0, M1, and M2 macrophages from a secretor-positive donor (four experiments). ( E ) Identification of norovirus-infected cells in M2 macrophages from a secretor-positive donor at 1 dpi by immunofluorescence assay. dsRNA, green; VP1, red; DAPI, blue. Scale bars, 10 μm. ( F ) Extracellular viral RNA levels following untreated or UV-inactivated GII.4[P16] inoculation onto M2 macrophages from a secretor-positive donor (duplicate/triplicate experiments). ( G ) Restricted replication of GII.4[P16] (9.34 × 10 4 copies) or GII.3[P21] (3.09 × 10 5 copies) in M2 macrophages (Secretor-positive donor) with or without GCDCA (500 μM; duplicate experiments). ( H ) Extracellular viral RNA levels in M2 macrophages from Pts. 1 and 2 following GII.4[P31] inoculation (3.92 × 10 5 copies). ( I ) Detection of norovirus-infected cells in M2 macrophages (Pt. 1) at 1 dpi by immunofluorescence assay. dsRNA, green; VP1, red. Scale bars, 5 μm. Viral RNA was quantified by RT-qPCR. Statistics: two-way ANOVA with Tukey’s multiple-comparisons test [(C), (D), (F), and (G)] and two-way ANOVA with uncorrected Fisher’s LSD (H). * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001.

    Article Snippet: The cells were cultured with human M-CSF (50 ng/ml; R&D system, catalog no. 216-MC, M0 macrophages), human GM-CSF (50 ng/ml; R&D system, catalog no. 215-GM, M1 macrophages) or human M-CSF (50 ng/ml) plus dexamethasone (1 μM; Sigma-Aldrich, catalog no. D2915, M2 macrophages) in RPMI1640 (Thermo Fisher Scientific, catalog no. 11875-093) medium supplemented with 10% FBS and penicillin (100 U/ml) and streptomycin (100 μg/ml) in a 96-well culture plate ( , , ).

    Techniques: Derivative Assay, Gene Expression, RNA Sequencing, Infection, Immunofluorescence, Quantitative RT-PCR